Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?

被引：20
作者：
Banan, Mehdi [1 ]
机构：
[1] Univ Social Welf & Rehabil Sci, Genet Res Ctr, Tehran, Iran
来源：
ANNALS OF HEMATOLOGY | 2013年 / 92卷 / 03期
关键词：
beta-thalassemia; Hydroxyurea; Pharmacogenomics; HbF; SICKLE-CELL-ANEMIA; GAMMA-GLOBIN GENE; FETAL-HEMOGLOBIN INDUCTION; HISTONE DEACETYLASE INHIBITORS; CULTURED ERYTHROID-CELLS; GENOME-WIDE ASSOCIATION; HEREDITARY PERSISTENCE; NITRIC-OXIDE; HBF LEVELS; IN-VITRO;
D O I：
10.1007/s00277-012-1671-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hydroxyurea (HU) is a drug that induces fetal hemoglobin production. As a result, HU is widely used to treat beta-thalassemia (beta-thal) patients. However, the response of these patients to HU varies. Some beta-thal patients respond favorably to treatment while others do not respond at all. HU has a number of side-effects and therefore its targeted prescription is beneficial. Hence, identifying the genetic determinants which lead to the differential HU response is important. This review summarizes recent findings which have shed light on this topic. Special emphasis is given to the mechanisms and genetic loci which may govern these differences. These findings have helped identify several single nucleotide polymorphisms which associate with the response to HU in both beta-thal and sickle cell disease patients.
引用
收藏
页码：289 / 299
页数：11
相关论文
共 110 条
[1]   Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening [J].
Alebouyeh, M ;
Moussavi, F ;
Haddad-Deylami, H ;
Vossough, P .
ANNALS OF HEMATOLOGY, 2004, 83 (07) :430-433
[2]   SEQUENCES LOCATED 3' TO THE BREAKPOINT OF THE HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN-3 DELETION EXHIBIT ENHANCER ACTIVITY AND CAN MODIFY THE DEVELOPMENTAL EXPRESSION OF THE HUMAN FETAL A-GAMMA-GLOBIN GENE IN TRANSGENIC MICE [J].
ANAGNOU, NP ;
PEREZSTABLE, C ;
GELINAS, R ;
COSTANTINI, F ;
LIAPAKI, K ;
CONSTANTOPOULOU, M ;
KOSTEAS, T ;
MOSCHONAS, NK ;
STAMATOYANNOPOULOS, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (17) :10256-10263
[3]   Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT) [J].
Ansari, Saqib H. ;
Shamsi, Tahir S. ;
Siddiqui, Fahad J. ;
Irfan, Muhammad ;
Perveen, Kausar ;
Farzana, Tasneem ;
Panjwani, Vinodh K. ;
Yousuf, Ayesha ;
Mehboob, Tabassui .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (11) :743-746
[4]  
Ataga Kenneth I, 2009, Hematology Am Soc Hematol Educ Program, P54, DOI 10.1182/asheducation-2009.1.54
[5]  
Atweh George F, 2003, Hematology Am Soc Hematol Educ Program, P14, DOI 10.1182/asheducation-2003.1.14
[6]   Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease [J].
Badens, Catherine ;
Joly, Philippe ;
Agouti, Imane ;
Thuret, Isabelle ;
Gonnet, Katia ;
Fattoum, Synda ;
Francina, Alain ;
Simeoni, Marie-Claude ;
Loundou, Anderson ;
Pissard, Serge .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (11) :1712-1714
[7]   The ins and outs of RNAi in mammalian cells [J].
Banan, M ;
Puri, N .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (05) :441-450
[8]  
Banan M, 2013, HEMOGLOBIN IN PRESS
[9]   THE XmnI AND BCL11A SINGLE NUCLEOTIDE POLYMORPHISMS MAY HELP PREDICT HYDROXYUREA RESPONSE IN IRANIAN β-THALASSEMIA PATIENTS [J].
Banan, Mehdi ;
Bayat, Hadi ;
Azarkeivan, Azita ;
Mohammadparast, Saeid ;
Kamali, Koorosh ;
Farashi, Samaneh ;
Bayat, Nooshin ;
Khani, Masumeh Hadavand ;
Neishabury, Maryam ;
Najmabadi, Hossein .
HEMOGLOBIN, 2012, 36 (04) :371-380
[10]   cAMP response element-binding protein 1 is required for hydroxyurea-mediated induction of γ-globin expression in K562 cells [J].
Banan, Mehdi ;
Esmaeilzadeh-Gharehdaghi, Elika ;
Nezami, Majid ;
Deilami, Zahra ;
Farashi, Samaneh ;
Philipsen, Sjaak ;
Esteghamat, Fatemehsadat ;
Pourfarzad, Farzin ;
Imam, A. M. Ali ;
Najmabadi, Hossein .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (06) :510-517
12345678910